Brickell Biotech Inc (NASDAQ:BBI)

0.8583
Delayed Data
As of Jun 15
 -0.0114 / -1.31%
Today’s Change
0.47
Today|||52-Week Range
2.61
+9.97%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$59.5M

Company Description

Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

Contact Information

Brickell Biotech, Inc.
5777 Central Avenue
Boulder Colorado 80301
P:(720) 505-4755
Investor Relations:

Employees

Shareholders

Mutual fund holders5.21%
Other institutional4.92%
Individual stakeholders3.57%

Top Executives

Robert B. BrownChief Executive Officer & Director
Andrew D. SklawerChief Operating Officer & Secretary
Albert N. MarchioChief Financial Officer
Deepak ChadhaChief Research & Development Officer
Nancy SerettaHead-Clinical Operations